Fungal diseases range from mild skin irritations that clear up with an over-the-counter cream to invasive bloodstream infections that can be fatal, and the type you get depends largely on which fungus is involved and how well your immune system is functioning. Millions of fungal species exist in the environment, yet fewer than a few hundred routinely cause disease in humans, in part because our body temperature itself acts as a powerful shield. When that shield is weakened by immunosuppression, medical devices, or certain environmental exposures, fungi can exploit the opening with remarkable tenacity.
Why Your Body Temperature Is Your First Defense
One of the most underappreciated reasons fungi cause relatively few problems in humans compared to plants or cold-blooded animals is simple heat. Most fungal species thrive at cooler ambient temperatures and cannot survive at 37 °C, the normal temperature of the human body. Research modeling the relationship between temperature tolerance and fungal growth has shown that mammalian body heat creates what amounts to an exclusionary thermal zone, blocking the vast majority of environmental fungi from ever gaining a foothold.1PubMed Central. Mammalian endothermy optimally restricts fungi and metabolic costs This idea helps explain why fungal infections are far more devastating in insects and amphibians, whose lower body temperatures offer less resistance.
The fungi that do infect warm-blooded hosts have evolved specific workarounds. A group known as thermally dimorphic fungi can switch their physical form depending on temperature. At cooler environmental temperatures (around 22–25 °C) they grow as mold with thread-like filaments, but once inside a mammalian host at 37 °C they convert to a yeast form. This shape-shifting is not cosmetic; it is directly tied to the organism’s ability to cause disease. The conversion to yeast inside the host is essential for virulence.2PubMed Central. Fungal Dimorphism and Virulence: Molecular Mechanisms for Temperature Adaptation, Immune Evasion, and In Vivo Survival Specific regulatory factors inside these fungi control the activation of virulence genes when temperature rises, essentially flipping a genetic switch that turns a harmless environmental mold into a pathogen.3PLoS Biology. A Temperature-Responsive Network Links Cell Shape and Virulence Traits in a Primary Fungal Pathogen
Superficial and Skin Infections
The fungal infections most people encounter are superficial: athlete’s foot, jock itch, ringworm, and nail fungus. These are caused by dermatophytes, a group of fungi that have evolved to feed on keratin, the tough protein in your skin, hair, and nails. Dermatophytes don’t typically invade deeper tissues. Instead, they stay on the surface, digesting keratin with specialized enzymes. During the early stages of infection, the fungi sense and adapt to the acidic environment of the skin. As they grow and break down keratin, they shift the local environment from acidic to alkaline, which happens to be exactly where their protein-digesting enzymes work best.4PubMed. Pathogenesis of Dermatophytosis: Sensing the Host Tissue
Superficial infections are common and rarely dangerous. They spread easily through direct contact or contaminated surfaces like gym floors, shared towels, and locker rooms. Treatment for most dermatophyte infections is straightforward: topical antifungal creams containing agents like terbinafine or clotrimazole resolve most cases within a few weeks. Nail infections are the stubborn exception, often requiring months of oral antifungal medication because topical treatments have difficulty penetrating the nail plate. Another superficial category includes yeast-driven conditions like oral thrush and vaginal candidiasis, both caused by overgrowth of Candida species that normally live harmlessly on your mucous membranes.
Opportunistic Systemic Infections
The fungal infections that land people in hospitals and sometimes prove fatal are opportunistic systemic mycoses. These are caused by organisms like Candida, Aspergillus, and Cryptococcus, which take advantage of a weakened immune system. Healthy people breathe in Aspergillus spores every day without consequence, and most carry Candida on their skin and in their gut with no issues. Problems arise when the immune system is suppressed by chemotherapy, organ transplantation, long-term steroid use, HIV/AIDS, or critical illness.
Invasive aspergillosis typically starts in the lungs after a person inhales spores of the Aspergillus mold. In immunocompromised patients the infection can be life-threatening, and its severity is shaped by the patient’s underlying conditions, the degree of immune suppression, and medications being used.5PubMed Central. Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review Risk factors extend beyond cancer and AIDS to include liver disease, organ transplantation, and prolonged stays in intensive care.6Sveikatos mokslai. INVASIVE PULMONARY ASPERGILLOSIS: RISK FACTORS, DIAGNOSIS AND TREATMENT PRINCIPLES
Cryptococcus neoformans is an encapsulated yeast found widely in soil and bird droppings. It is particularly dangerous because of its ability to cross the blood-brain barrier and cause meningitis. Its main weapon is a thick polysaccharide capsule that helps it evade the immune system and that changes its structure as the organism invades different organs.7PubMed Central. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier During infection, the capsule is released in large quantities and actively suppresses the host’s immune response, making cryptococcal meningitis especially devastating in people with AIDS.8PubMed Central. Cryptococcus neoformans-astrocyte interactions: effect on fungal blood brain barrier disruption, brain invasion, and meningitis progression
Endemic Fungi and Geographic Risk
Some fungal diseases are tied to specific regions of the world. Histoplasmosis, caused by Histoplasma capsulatum, is concentrated in the Ohio and Mississippi River valleys in the United States and in parts of Central America. The fungus lives in soil enriched by bat and bird droppings. People become infected by inhaling spores that are kicked up when contaminated soil is disturbed, whether through construction, farming, or exploring caves. Resulting lung infections range from completely asymptomatic to severe disseminated disease.9PubMed. Environmental and Wilderness-Related Risk Factors for Histoplasmosis: More Than Bats in Caves Coccidioidomycosis, commonly called valley fever, follows a similar pattern in the arid soils of the southwestern United States and parts of Mexico and South America.
An important clinical wrinkle with endemic fungal diseases is that symptoms can appear long after a person has left the area where they were exposed. Someone who lived in an endemic zone years ago might develop reactivation disease after their immune system declines for any reason, which can lead to diagnostic confusion if the physician isn’t thinking about fungi.10PubMed Central. Fungal infections This delayed presentation means that geographic history matters even decades later.
The Candida auris Problem
If one fungal species has earned the label of urgent public health threat in recent years, it is Candida auris. First identified in 2009, this yeast has since caused outbreaks in healthcare facilities across more than twenty countries on five continents.11Medical Mycology. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen What makes it so alarming is a combination of traits that most Candida species lack: it resists multiple classes of antifungal drugs, it colonizes patients for extended periods, it persists on environmental surfaces in hospitals, and it spreads readily between patients.12PLoS Pathogens. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally
Adding to the challenge, C. auris is frequently misidentified by standard laboratory methods, meaning outbreaks can smolder undetected. It primarily causes invasive bloodstream infections in immunocompromised patients, and the difficulty of treatment is compounded by resistance to multiple antifungal agents.13PubMed Central. The rising challenge of Candida auris: insights into its transmission, drug resistance, and infection control strategies Healthcare facilities dealing with C. auris outbreaks have had to implement strict infection-control protocols, including enhanced environmental cleaning and patient screening, to contain spread.
Biofilms and Why Some Infections Keep Coming Back
One of the reasons fungal infections can be so stubborn, whether on a denture, an intravenous catheter, or a urinary device, is the ability of many fungi to form biofilms. A biofilm is a structured community of cells that adheres to a surface and surrounds itself in a protective matrix. Cells living inside a biofilm behave very differently from free-floating cells. They tolerate much higher concentrations of antifungal drugs and resist the host’s immune defenses more effectively, making biofilm infections extremely difficult to clear.14PubMed Central. Fungal biofilms, drug resistance, and recurrent infection
Biofilm formation on implanted medical devices is a major driver of recurrent fungal infections, and most available antifungals have minimal activity against established biofilms.15PubMed Central. Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs In Candida infections specifically, biofilm-associated cells can withstand drug concentrations that would easily kill their free-floating counterparts.16PubMed Central. Antifungal drug-resistance mechanisms in Candida biofilms This often means that the only reliable way to cure a device-associated biofilm infection is to physically remove the device, which is not always straightforward when catheters or prosthetic joints are involved. Biofilm-like growth can also occur during mucosal infections such as oral thrush and vaginal candidiasis, even without a device present.
How Antifungal Drugs Work
Treating fungal infections is harder than treating bacterial infections, in part because fungal cells are much more similar to human cells than bacteria are. Both fungi and humans are eukaryotes, meaning their cells share basic structural features. That similarity limits the number of drug targets you can attack in the fungus without also harming the patient. Current antifungal drugs fall into a few main classes, each exploiting subtle molecular differences between fungal and human cells.
Azoles, including fluconazole and itraconazole, are the most widely used antifungals. They work by blocking an enzyme involved in producing ergosterol, a component of the fungal cell membrane that serves a function similar to cholesterol in human cells. When ergosterol production is disrupted, precursor molecules accumulate and the membrane becomes unstable, stunting fungal growth.17Acta Pharmaceutica Sinica B. Controlling antifungal activity with light: Optical regulation of fungal ergosterol biosynthetic pathway with photo-responsive CYP51 inhibitors Amphotericin B takes a more direct approach: it binds to ergosterol in the fungal membrane and punches holes in it, causing the cell’s contents to leak out and the cell to die. The problem is that amphotericin B can also bind to cholesterol in human cell membranes, which is why it has long been associated with kidney toxicity.18PubMed. Formulation Strategies to Overcome Amphotericin B Induced Toxicity
Echinocandins, a newer class including caspofungin and micafungin, target the fungal cell wall rather than the membrane. They block an enzyme needed to build a key structural component of the wall. Without that scaffolding, the wall weakens, the cell can’t maintain its internal pressure, and it dies.19PubMed Central. Echinocandins – structure, mechanism of action and use in antifungal therapy Because human cells don’t have cell walls at all, echinocandins tend to have fewer side effects, though they are only effective against certain types of fungi and currently must be given intravenously.
The Immune System’s Fungal Playbook
Your immune system uses several layers of defense against fungi, and the specific response depends on the type and location of the infection. On mucous membranes like the lining of the mouth, a signaling pathway involving IL-17 plays a central role. People who lack functional IL-17 signaling are strongly susceptible to oral candidiasis, in large part because the signal is needed to recruit neutrophils, a type of white blood cell, to the site of infection.20The Journal of Immunology. Role of Neutrophils in IL-17–Dependent Immunity to Mucosal Candidiasis Without enough neutrophils showing up, the fungus grows unchecked.
At an earlier stage of recognition, immune cells use pattern-recognition receptors to detect molecular signatures on fungal surfaces. These receptors bind to components like the carbohydrates found in fungal cell walls and trigger downstream immune activation.21Immunity. Dectin-3 Forms a Novel Heterodimeric Pattern Recognition Receptor with Dectin-2 for Host Defense against Fungal Infection The mycobiome, the fungal component of your normal microbial community, also plays a background role. A balanced fungal ecosystem in the gut and on the skin helps maintain immune homeostasis, and disruption of that balance in immunocompromised individuals can contribute to disease.22PubMed Central. The Human Mycobiome: Colonization, Composition and the Role in Health and Disease
Agricultural Fungicides and Drug Resistance
Here is a connection that surprises most people: the same class of antifungal chemicals used to protect wheat, tulips, and other crops from mold is closely related to the azole drugs used in hospitals. Triazole fungicides are sprayed widely in agriculture, and environmental Aspergillus fumigatus molds exposed to these chemicals can develop resistance mutations. Those resistant strains then end up inhaled by humans. The result is patients arriving at the hospital with azole-resistant aspergillosis who have never taken an antifungal drug in their lives.23PubMed Central. Azole Resistance in Aspergillus fumigatus: A Consequence of Antifungal Use in Agriculture?
The main resistance mechanism identified involves specific genetic changes in the Aspergillus gene targeted by azoles. The same mutation has been found in environmental isolates from agricultural soils and in clinical isolates from patients who were never previously treated, strongly suggesting that the resistance was acquired environmentally rather than during medical treatment. Agricultural triazole use in the United States increased substantially over recent decades, and certain resistant Aspergillus strains found in human disease have been linked to environmental fungicide exposure.24PubMed Central. Trends in Agricultural Triazole Fungicide Use in the United States, 1992-2016 and Possible Implications for Antifungal-Resistant Fungi in Human Disease This is a textbook example of how resistance is a shared problem across medicine and agriculture, much like the antibiotic-resistance story but less widely discussed.
Getting the Diagnosis Right
Fungal infections are often diagnosed late, partly because their symptoms overlap with bacterial infections and cancers, and partly because traditional diagnostic tools are slow. Growing a fungus in culture, the gold-standard method, can take days to weeks. In the meantime, a patient with invasive aspergillosis or candidemia may be deteriorating. This is an area where the technology has been evolving rapidly. Newer tools include molecular assays that detect fungal DNA directly from blood or tissue, microfluidic chip technology, and next-generation sequencing approaches that can identify the exact species involved in hours rather than days.25PubMed Central. Diagnosis of invasive fungal infections: challenges and recent developments Blood tests that detect fungal cell-wall components circulating in the bloodstream have also become routine in many hospitals, allowing earlier initiation of treatment while culture results are pending.
The speed-of-diagnosis problem is especially acute with C. auris, which as mentioned is frequently misidentified by standard methods. Laboratories that rely on older biochemical identification systems may report it as a different Candida species entirely, delaying appropriate infection control. Molecular identification methods have become the recommended approach for definitive diagnosis of this pathogen.
New Drugs and the Possibility of Vaccines
For decades the antifungal drug pipeline was nearly empty, leaving clinicians to rotate between the same handful of drug classes. That picture has started to change. Several new agents with novel mechanisms have reached late-stage clinical development or recent approval. These include ibrexafungerp, the first in a new class of antifungals that targets the fungal cell wall through a different mechanism than echinocandins, and rezafungin, a next-generation echinocandin designed for less frequent dosing. Other promising agents include fosmanogepix, which blocks an enzyme involved in anchoring proteins to the fungal cell surface, and olorofim, which interferes with a metabolic pathway essential for mold growth.26PubMed Central. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin Newer agents also aim for reduced toxicity compared to older drugs like amphotericin B.27PubMed. Antifungal pipeline: New tools for the treatment of mycoses
Perhaps the most ambitious frontier is fungal vaccines. No antifungal vaccine has been approved for human use, but research is progressing on candidates that could protect high-risk patients. One approach involves pan-fungal vaccines that target molecular structures shared across multiple disease-causing species. In animal models, a conjugate vaccine targeting a cell-wall sugar found on many pathogenic fungi protected mice against both Candida and Aspergillus infections. Another candidate, a synthetic peptide called NXT-2, was designed based on sequences shared among Pneumocystis, Aspergillus, Candida, and Cryptococcus, and reduced illness and death in animal models of invasive infection by these species.28PubMed Central. Vaccine development for pathogenic fungi: current status and future directions These are still in preclinical or early development, but they represent a genuinely new direction in a field where prevention has historically meant only avoiding exposure or taking prophylactic drugs.
Climate Change and Shifting Fungal Geography
Warming global temperatures may be redrawing the map of where pathogenic fungi can thrive. Modeling studies on Cryptococcus gattii, a relative of the species that causes cryptococcal meningitis, found that climate changes significantly expanded the range of environments suitable for the fungus across Europe. Between 1980 and 2009 the suitable area grew gradually, but in the decade from 2010 to 2019 the environmental surface where the fungus could survive more than doubled.29PubMed Central. Global warming impact on the expansion of fundamental niche of Cryptococcus gattii VGI in Europe There is also a broader theoretical concern: as environmental temperatures rise, fungi that currently cannot tolerate mammalian body heat may gradually adapt, potentially adding new species to the list of human pathogens. The thermal barrier that has protected mammals from most fungi for millions of years could, in theory, narrow as the environment pushes fungal thermal tolerance upward. Whether that scenario plays out meaningfully in human disease is still speculative, but it has motivated some researchers to argue that the fungal disease burden deserves more surveillance and funding than it currently receives.